All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Rini Expands on Key Clinical Trial Updates in GU Cancers from the 2023 ASCO Annual Meeting

July 20th 2023

Brian I. Rini, MD, FASCO, highlights key clinical trial updates from the genitourinary cancers landscape presented at the 2023 ASCO Annual Meeting, details the implications of the CONTACT-03 data, expands on the long-term data from the phase 3 KEYNOTE-426 trial in clear cell RCC, discusses findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer, and more.

APVO436 Plus Venetoclax/Azacitidine Produces Durable Remissions in Relapsed/Refractory AML

July 20th 2023

Treatment with the CD3 x CD123 bispecific antibody APVO436 plus venetoclax and azacitidine led to durable remissions in patients with relapsed/refractory acute myeloid leukemia who had not received prior venetoclax.

ENB-003 Plus Pembrolizumab Elicits Safety, Activity in Ovarian Cancer and Other Advanced, Refractory Solid Tumors

July 20th 2023

Treatment with the combination of ENB-003 and pembrolizumab was well tolerated and produced preliminary signs of clinical activity in patients with platinum-refractory or -resistant, microsatellite stable ovarian cancer, and those with other advanced refractory solid tumors.

Real-World Analysis Shows Brexu-Cel Elicits Higher CR Rate in Patients With R/R MCL Given Fewer Lines of Prior Therapy

July 20th 2023

Nausheen Ahmed, MD, explains the rationale for examining real-world outcomes observed with the use of brexu-cel in the treatment of patients with relapsed/refractory mantle cell lymphoma, details the key efficacy and safety findings from the overall population and different subgroups, and discusses what will be gained with longer follow-up of the study.

Cancer Center of Kansas Joins The US Oncology Network

July 20th 2023

The US Oncology Network announced that the Cancer Center of Kansas has joined The Network by entering into a new managed services partnership.

China’s NMPA Accepts sNDA for First-Line Toripalimab Plus Chemo in ES-SCLC

July 20th 2023

China’s National Medical Products Administration has accepted a supplemental new drug application seeking the approval of toripalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer.

Tislelizumab Plus Bevacizumab/Chemo Demonstrates Early Efficacy in Cervical Cancer

July 20th 2023

The addition of the PD-L1 inhibitor tislelizumab to standard bevacizumab and platinum-doublet chemotherapy in the first-line setting prolonged progression-free survival, produced encouraging responses, and was well tolerated in patients with cervical cancer.

FDA Awards Fast Track Designation to ARX517 for Metastatic Castration-Resistant Prostate Cancer

July 20th 2023

The FDA has granted fast track designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer who experience disease progression on an androgen receptor pathway inhibitor.

Bexmarilimab Plus SOC Continues to Show Early Activity in R/R AML and MDS

July 19th 2023

Bexmarilimab in combination with standard-of-care azacitidine or azacitidine plus venetoclax demonstrated early signs of efficacy in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.

Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 19th 2023

Neeraj Agarwal, MD, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC.

Diagnostic Advances Distinguish Actionable Drivers of Early Progression in ER+ Breast Cancer

July 19th 2023

Ahmed Elkhanany, MD discusses unmet needs in patients with estrogen receptor–positive breast cancer who progress on frontline therapy, treatment considerations for these patients, and how FES PET imaging may benefit this population.

Phase 1b Data Support Continued Investigation of Acalabrutinib Plus BR in MCL

July 19th 2023

Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population.

Theseus Pharmaceuticals Terminates Development of THE-630 in Gastrointestinal Stromal Tumors

July 19th 2023

Theseus Pharmaceuticals has announced that the development of THE-630 as a potential therapeutic option for patients with gastrointestinal stromal tumor has been terminated, and enrollment to the ongoing phase 1/2 trial evaluating the agent’s safety and efficacy in this population has been discontinued.

Time to Treatment Matters After a Cancer Diagnosis

July 19th 2023

Finding a comprehensive cancer care provider that is able to provide patients with swift and easy access to the highest-quality diagnosis and treatment planning is essential to reducing stress and ensuring patients achieve the best possible outcomes.

Pembrolizumab Plus Chemoradiotherapy Meets PFS End Point in High-Risk Locally Advanced Cervical Cancer

July 19th 2023

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, improved progression-free survival vs concurrent chemoradiotherapy alone in newly diagnosed patients with high-risk locally advanced cervical cancer.

FDA Grants Fast Track Status to Selinexor for Myelofibrosis

July 19th 2023

The FDA has granted a fast track designation to selinexor for use in the treatment of patients with myelofibrosis, including primary myelofibrosis, post–essential thrombocytopenia myelofibrosis, and post–polycythemia vera myelofibrosis.

IMX-110 Plus Tislelizumab Leads to Tumor Shrinkage in Heavily Pretreated mCRC

July 19th 2023

Treatment with the combination of the tissue-specific therapeutic IMX-110 and the anti–PD-1 antibody tislelizumab led to tumor shrinkage in heavily pretreated patients with metastatic colorectal cancer.

Lazertinib Outperforms Gefitinib in EGFR-Mutated NSCLC

July 18th 2023

The third-generation EGFR TKI lazertinib displayed a significant efficacy improvement compared with gefitinib in patients with EGFR-mutated advanced non–small cell lung cancer when given in the first-line.

Combination Approaches Are on the Horizon in Later-Line HER2+ Breast Cancer Management

July 18th 2023

Adrienne G. Waks, MD, spotlights the need to understand mechanisms of resistance to second-line HER2-positive breast cancer therapies, chemotherapy-free regimens with later-line treatment potential, and the future of HER2-positive disease management.

Breast Cancer Research Breakthroughs Signal Paradigm Shifts Across Disease Subsets

July 18th 2023

Maryam Lustberg, MD, MPH, discusses insights regarding other key breast cancer data presented at the 2023 ASCO Annual Meeting, including findings from the phase 3 BWEL trial, updated data from the phase 2 ELAINE-2 trial, and the final overall survival analysis of the phase 3 TROPiCS-02 trial.